IDH1 and astrocytoma (excluding glioblastoma): Notably, vorasidenib received approval from the United States Food and Drug Administration (FDA) in August 2024 for the treatment of grade 2 oligodendroglioma and grade 2 IDH-mutant astrocytoma (2).